Why the study?
Does the clinical efficacy of metoprolol depend on its salt formulation or release presentation in patients with cardiovascular diseases?
Does the clinical efficacy of metoprolol depend on its salt formulation or release presentation in patients with cardiovascular diseases?
The pharmacodynamic properties of metoprolol depend solely on the active molecule, while its clinical efficacy and indications in various cardiovascular diseases are influenced by the release kinetics of its different salt formulations.
Answers are grounded in this paper and cite their sources.
Release kinetics may influence metoprolol efficacy; leaves open whether salt formulations affect cardiovascular outcomes.
Relationship of metoprolol clinical efficacy with its different salts (tartrate, succinate, fumarate) as well as its presentations (tablets with immediate, controlled or sustained release) is analyzed. It is highlighted that pharmacodynamic properties depend on metoprolol molecule only. These properties do not change after modification of drug presentation or metoprolol plasma concentration which depends on velocity of drug release from the tablet. Data of randomized clinical trials are discussed in regard to development of evidence base for use of different metoprolol presentations in treatment of patients with arterial hypertension, unstable angina, myocardial infarction, heart failure. Indications for tartrate and succinate salts of metoprolol are presented. Results of clinical studies on efficacy of metoprolol tartrate in long-acting drug presentations are analyzed.
No takes yet. Share an insight, caveat, or question.
Э. В. Кулешова (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: